Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;73(10):1886-1895.
doi: 10.1002/art.41743. Epub 2021 Aug 31.

Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS

Marcela A Ferrada  1 , Keith A Sikora  1 , Yiming Luo  1 , Kristina V Wells  1 , Bhavisha Patel  2 , Emma M Groarke  2 , Daniela Ospina Cardona  3 , Emily Rominger  1 , Patrycja Hoffmann  3 , Mimi T Le  1 , Zuoming Deng  1 , Kaitlin A Quinn  1 , Emily Rose  1 , Wanxia L Tsai  1 , Gustaf Wigerblad  1 , Wendy Goodspeed  1 , Anne Jones  3 , Lorena Wilson  3 , Oskar Schnappauf  3 , Ryan S Laird  3 , Jeff Kim  4 , Clint Allen  4 , Arlene Sirajuddin  2 , Marcus Chen  2 , Massimo Gadina  1 , Katherine R Calvo  5 , Mariana J Kaplan  1 , Robert A Colbert  1 , Ivona Aksentijevich  3 , Neal S Young  2 , Sinisa Savic  6 , Daniel L Kastner  3 , Amanda K Ombrello  3 , David B Beck  3 , Peter C Grayson  1
Affiliations

Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS

Marcela A Ferrada et al. Arthritis Rheumatol. 2021 Oct.

Abstract

Objective: Somatic mutations in UBA1 cause a newly defined syndrome known as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome). More than 50% of patients currently identified as having VEXAS met diagnostic criteria for relapsing polychondritis (RP), but clinical features that characterize VEXAS within a cohort of patients with RP have not been defined. We undertook this study to define the prevalence of somatic mutations in UBA1 in patients with RP and to create an algorithm to identify patients with genetically confirmed VEXAS among those with RP.

Methods: Exome and targeted sequencing of UBA1 was performed in a prospective observational cohort of patients with RP. Clinical and immunologic characteristics of patients with RP were compared based on the presence or absence of UBA1 mutations. The random forest method was used to derive a clinical algorithm to identify patients with UBA1 mutations.

Results: Seven of 92 patients with RP (7.6%) had UBA1 mutations (referred to here as VEXAS-RP). Patients with VEXAS-RP were all male, were on average ≥45 years of age at disease onset, and commonly had fever, ear chondritis, skin involvement, deep vein thrombosis, and pulmonary infiltrates. No patient with VEXAS-RP had chondritis of the airways or costochondritis. Mortality was greater in VEXAS-RP than in RP (23% versus 4%; P = 0.029). Elevated acute-phase reactants and hematologic abnormalities (e.g., macrocytic anemia, thrombocytopenia, lymphopenia, multiple myeloma, myelodysplastic syndrome) were prevalent in VEXAS-RP. A decision tree algorithm based on male sex, a mean corpuscular volume >100 fl, and a platelet count <200 ×103 /μl differentiated VEXAS-RP from RP with 100% sensitivity and 96% specificity.

Conclusion: Mutations in UBA1 were causal for disease in a subset of patients with RP. This subset of patients was defined by disease onset in the fifth decade of life or later, male sex, ear/nose chondritis, and hematologic abnormalities. Early identification is important in VEXAS given the associated high mortality rate.

PubMed Disclaimer

Comment in

References

    1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020;383:2628-38.
    1. Dion J, Costedoat-Chalumeau N, Sène D, Cohen-Bittan J, Leroux G, Dion C, et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142 patients. Arthritis Rheumatol 2016;68:2992-3001.
    1. Shimizu J, Yamano Y, Kawahata K, Suzuki N. Relapsing polychondritis patients were divided into three subgroups: patients with respiratory involvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patients with both involvements (O subgroup), and each group had distinctive clinical characteristics. Medicine (Baltimore) 2018;97:e12837.
    1. Ferrada M, Rimland CA, Quinn K, Sikora K, Kim J, Allen C, et al. Defining clinical subgroups in relapsing polychondritis: a prospective observational cohort study. Arthritis Rheumatol 2020;72:1396-402.
    1. Washio K, Oka M, Ohno K, Shimizu H, Kawano S, Kunisada M, et al. Case of recurrent Sweet's syndrome in a patient with relapsing polychondritis and myelodysplastic syndrome. J Dermatol 2012;39:731-3.

Publication types

Substances

LinkOut - more resources